The general meeting of shareholders in Sopharma Trading Sofia approved capital increase from 20 mln leva (10.255 mln euros) to 30 mln leva (15.338 mln euros), via the issuance of 10 mln common, registered, paperlsess, voting shares with a face value of 1 lev.

Shareholders will receive new shares in a proprtion to their interest in the capital prior to its increase – one new share per two of the already existing shares.

The general meeting announced a one month period within which shareholders may subscribe new shares, depositting 25% of their value.

If part of the shares remain unsubcribed within the deadline, an amount of them (worth up to 30 mln leva) may be subscribed by shareholders (who subcribed shares within the one month deadline) in an additional one week period, and under the same old/new shares proportion.

The capital increase takes the company one step closer to its BSE listing. Sopharma is also planning a secondary public offering till the end of the year.

Principal shareholders are Telso AD controlling 45.33% of the capital, Bulgarian-American Investment Fund with 33.4% and Tatyana Draculova with 11%.